scholarly journals Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering

2021 ◽  
Vol 144 ◽  
pp. 112222
Author(s):  
Xianyu Hu ◽  
Zhenglin Wang ◽  
Qing Wang ◽  
Ke Chen ◽  
Qijun Han ◽  
...  
2018 ◽  
pp. 279-294
Author(s):  
Abdullah Jibawi ◽  
Mohamed Baguneid ◽  
Arnab Bhowmick

Gastric cancer presents in the majority of cases at a locally advanced/metastatic stage. Initial investigations should be on the dyspepsia pathway. Multiple biopsies are necessary from any suspicious endoscopic lesions. Accurate staging and MDT assessment is essential for optimum patient selection for surgery. Endoscopic resection can now be recommended for very early lesions with good prognostic features. In gastrectomy, controversy exists across the world as to the extent of lymphadenectomy. This is discussed, as well as neoadjuvant and adjuvant oncological therapy.


Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1863
Author(s):  
Mauricio P. Pinto ◽  
Miguel Córdova-Delgado ◽  
Ignacio N. Retamal ◽  
Matías Muñoz-Medel ◽  
M. Loreto Bravo ◽  
...  

Gastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these systems require high-cost and complex techniques and consequently their impact in the clinic has remained limited. Additionally, most of these studies are based on European, Asian, or North American GC cohorts. Herein, we report a molecular classification of Chilean GC patients into five subtypes, based on immunohistochemical (IHC) and in situ hybridization (ISH) methods. These were Epstein–Barr virus positive (EBV+), mismatch repair-deficient (MMR-D), epithelial to mesenchymal transition (EMT)-like, and accumulated (p53+) or undetected p53 (p53−). Given its lower costs this system has the potential for clinical applicability. Our results confirm relevant molecular alterations previously reported by TCGA and ACRG. We confirm EBV+ and MMR-D patients had the best prognosis and could be candidates for immunotherapy. Conversely, EMT-like displayed the poorest prognosis; our data suggest FGFR2 or KRAS could serve as potential actionable targets for these patients. Finally, we propose a low-cost step-by-step stratification system for GC patients. To the best of our knowledge, this is the first Latin American report on a molecular classification for GC. Pending further validation, this stratification system could be implemented into the routine clinic


2015 ◽  
Vol 13 ◽  
pp. 448-458 ◽  
Author(s):  
Xiandong Lin ◽  
Yongzhong Zhao ◽  
Won-min Song ◽  
Bin Zhang

2016 ◽  
Vol 60 (2) ◽  
pp. 126-137 ◽  
Author(s):  
Jiawei Guo ◽  
Weiwei Yu ◽  
Hui Su ◽  
Xiufeng Pang

2016 ◽  
Vol 27 (5) ◽  
pp. 763-769 ◽  
Author(s):  
N.-Y. Chia ◽  
P. Tan

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Helena Magalhães ◽  
Mário Fontes-Sousa ◽  
Manuela Machado

Gastric cancer (GC) remains a public health problem, being the fifth most common cancer worldwide. In the western countries, the majority of patients present with advanced disease. Additionally, 65 to 75% of patients treated with curative intent will relapse and develop systemic disease. In metastatic disease, systemic treatment still represents the state of the art, with less than a year of median overall survival. The new molecular classification of GC was published in 2014, identifying four distinct major subtypes of gastric cancer, and has encouraged the investigation of new and more personalized treatment strategies. This paper will review the current evidence of immunotherapy in advanced gastric cancer.


Sign in / Sign up

Export Citation Format

Share Document